Law360, Los Angeles (February 12, 2013, 7:41 PM EST) -- Pharmaceutical giant Bristol-Myers Squibb Co. has signed off on a $438 million collaboration agreement giving British manufacturer Reckitt Benckiser Group PLC exclusive rights to sell several of the drugmaker’s Latin American medications, the companies announced Tuesday.
Under the terms of the three-year deal, Reckitt Benckiser will pay Bristol-Myers $438 million upfront for the rights to sell, distribute and market several over-the-counter medications Bristol-Myers currently sells in Mexico, Brazil and other parts of Latin America, with an option to purchase the drugs at the end of the...
Bristol-Myers Inks $440M Sales Deal With Reckitt Benckiser
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
